Lipopolysaccharide

Phase 1Small molecule

Boehringer Ingelheim

Lipopolysaccharide is one of 73 small molecule programs targeting Inflammatory Response. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory ResponseActive, not recruiting

HypoxiaActive, not recruiting

Inflammatory ResponsePhase 1

Active, not recruiting

HypoxiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Inflammatory Response

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Cyklokapron

AAmring

Phase 3

1 3

Arcoxia

Novartis

Phase 2

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

5 5

Chirocaine

PPurdue Pharma LP

Phase 2

1 6

Ketalar

AAultman Health Foundation

Phase 2

1 7

Bayer Aspirin

Bayer

Phase 1

1 8

Tysabri

Biogen

Phase 1

1 9

Trexall

Alnylam Pharmaceuticals

Preclinical

1 10

MS Contin

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Parkinson's Disease

NCT05205291

Q4 2026

N/ARecruiting

Inflammation

NCT06620679

Clinical

Trials by Indication[1]

Depression3 trials

Theophylline for Depression Study

Withdrawn·UUniversity of California, Los Angeles·Phase 1·NCT04309877

Leucine for Depression Study (L-DEP)

Terminated·UUniversity of California, Los Angeles·Phase 1·NCT03557684·59 enrolled

Lipopolysaccharide (LPS) Challenge in Depression

Completed·LLaureate Institute for Brain Research, Inc.·Phase 1·NCT03142919·64 enrolled

Immune Response2 trials

Neuroimmune Response to Lipopolysaccharide

Completed·YYale University·Phase 1·NCT04233593·27 enrolled

The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia

Completed·RRadboud University Medical Center··NCT01352871·1 enrolled

Inflammation2 trials

Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT06620679·20 enrolled

Inflammation and Brain Function - Pilot Study

Completed·KKarolinska Institutet·N/A·NCT03551080·8 enrolled

Immune System1 trial

Imaging the Neuroimmune System in PTSD

Completed·YYale University·Phase 1·NCT04236986·34 enrolled

Parkinson's Disease1 trial

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

Recruiting·—··NCT05205291·30 enrolled

8 more indications

Hypoxia1 trial

Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α

Completed·RRadboud University Medical Center·Phase 1/2·NCT01978158·30 enrolled

Function1 trial

Effect of Lipopolysaccharide on Skeletal Muscle Functions

Completed·UUniversity of Nottingham·N/A·NCT01423968·6 enrolled

Inflammatory Mediators1 trial

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05884242·20 enrolled

Immunotherapy1 trial

Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal

Completed·—·Phase 1·NCT05751837·10 enrolled

Concentration1 trial

Concentration/Meditation Limits Inflammation

Completed·RRadboud University Medical Center·N/A·NCT01835457·30 enrolled

Inflammatory Response1 trial

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02211170·24 enrolled

Endotoxemia1 trial

Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide

Completed·BBernd Jilma·Phase 4·NCT02876601·20 enrolled

Age1 trial

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT03306589·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Lipopolysaccharide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipopolysaccharide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipopolysaccharide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Boehringer Ingelheim

Lipopolysaccharide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Depression3 trials

Immune Response2 trials

Inflammation2 trials

Immune System1 trial

Parkinson's Disease1 trial

Hypoxia1 trial

Function1 trial

Inflammatory Mediators1 trial

Immunotherapy1 trial

Concentration1 trial

Inflammatory Response1 trial

Endotoxemia1 trial

Age1 trial

References

Drug Info

Quick Facts

Related News